177Lu-Edotreotide (177Lu–Octreotide, 177Lu-Solucin®) is a radiolabeled somatostatin analogue developed for the treatment of NET. It is derived from the equivalent 90Y-Edotreotide originally developed under the name Onalta®.
177Lu-Edotreotide obtained the Orphan Drug designation from the EMA in July 2014 and from the FDA in June 2015 for the indication P-NET (pancreatic neuroendocrine tumors).
177Lu-Edotreotide will be developed for the treatment of patients with gastro-entero-pancreatic neuroendocrine tumors (GEP-NET). This molecule must be considered as a competitor for the analogue 177Lu-Oxodotreotide (177Lu-Lutathera®).
A Phase III trial involving 300 patients was initiated in February 2017. This study is supposed to be completed by June 2024. Another Phase III trial (COMPOSE) was initiated in December 2021 with completion expected in September 2026.
Target/Mechanism: somatostatin receptors
Radiation type: beta electrons (β–)